TD Cowen initiated coverage on Astria Therapeutics with a new price target
$ATXS
Biotechnology: Pharmaceutical Preparations
Health Care
TD Cowen initiated coverage of Astria Therapeutics with a rating of Buy and set a new price target of $35.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/31/2025 | $26.00 | Mkt Outperform | JMP Securities |
| 7/29/2024 | $35.00 | Buy | TD Cowen |
| 3/28/2023 | $18.00 | Outperform | Evercore ISI |
| 9/29/2021 | $20.00 | Buy | Jefferies |
JMP Securities initiated coverage of Astria Therapeutics with a rating of Mkt Outperform and set a new price target of $26.00
TD Cowen initiated coverage of Astria Therapeutics with a rating of Buy and set a new price target of $35.00
Evercore ISI initiated coverage of Astria Therapeutics with a rating of Outperform and set a new price target of $18.00
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
10-K - Astria Therapeutics, Inc. (0001454789) (Filer)
8-K - Astria Therapeutics, Inc. (0001454789) (Filer)
SCHEDULE 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the appointment of Sunil Agarwal, M.D., to its Board of Directors. Dr. Agarwal has more than 20 years of biotechnology research, development, and commercialization experience. "It is a pleasure to welcome Sunil to our Board of Directors," said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. "His extensive drug development and clinical expertise strongly complements our Board's skills and experiences, and we look forward to his contributions as we continue to advance our programs into later-stage cl
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
-- ALPHA-ORBIT Pivotal Phase 3 Trial Evaluating Every 3- and Every 6-Month Administration of Navenibart (STAR-0215) in Hereditary Angioedema is Underway -- -- Initial Efficacy and Safety Data from Navenibart ALPHA-SOLAR Long-Term Extension Trial Expected Mid-2025 -- -- Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist, Ongoing with Initial Results Anticipated in Q3 2025 -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate updat
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 87,450 shares of Astria's common stock on March 3, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were granted as an inducement material to five employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $6.10, which is equal to the closing price of Astria
-- Trial Designed to Demonstrate Efficacy and Safety of Every 3- and Every 6-Month Administration in a 6-Month Treatment Period -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced the initiation of the ALPHA-ORBIT Phase 3 clinical trial of navenibart in people living with hereditary angioedema (HAE). Navenibart has the potential to provide rapid and sustained HAE attack prevention with a very low treatment burden and administration every 3 months (Q3M) and every 6 months (Q6M). "We believe that navenibart will deliver strong efficacy, low treatment burden, and favorab
SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)
SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)
SC 13D/A - Astria Therapeutics, Inc. (0001454789) (Subject)
-- STAR-0215 Dosed Once or Twice Over 6 Months Reduced Monthly Attack Rates by 90-96%, Supporting Chronic Dosing 2 or 4 Times Per Year -- -- 92-100% Decrease in Moderate or Severe Attacks and 91-95% Reduction in Attacks Requiring Rescue Medications with STAR-0215 -- -- Very Well-Tolerated with No Serious Adverse Events and No Discontinuations -- -- Phase 3 Initiation on Track for Q1 2025, with Top-Line Results Expected by Year End 2026 -- -- Current Cash Expected to Fund Company into Mid-2027 -- -- Conference Call Today at 8:30am ET – Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, will report third quarter 2023 financial results before the Nasdaq Global Market open on Monday, November 13, 2023. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss third quarter financial results. Webcast Information: Interested parties may join the webcast via the Investors section of the Astria website, www.astriatx.com, or with the following link: https://lifescievents.com/event/astria-2/. Please connect to the webca
-- Differentiated Preclinical Lead Candidate STAR-0310 to be Developed as a Potential Best-in-Class Long-Acting Treatment for Atopic Dermatitis – -- Conference Call and Webcast to be Held on October 12, 2023 at 8:30am ET -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it has entered into a worldwide exclusive license agreement with Ichnos Sciences for an OX40 portfolio to be developed for the potential treatment of atopic dermatitis (AD) and potentially for other allergic and immunological diseases. Astria plans to develop the lead candidate, called STAR-03